Evaluable Responses to Clofazimine
| Organ Involvement . | No. . | NR (%) . | Stable (%) . | PR (%) . | CR (%) . |
|---|---|---|---|---|---|
| Skin3-150 | 16 | 4/16 (25) | 3/16 (19) | 9/16 (56) | — |
| Joints (flexion contractures) | 11 | 3/11 (27) | 1/11 (9) | 3/11 (27) | 4/11 (36) |
| Mouth (sores, pain) | 6 | 2/6 (33) | 1/6 (17) | 3/6 (50) | — |
| Lungs (bronchiolitis obliterans) | 4 | 2/4 (50) | 1/4 (25) | 1/4 (25) | — |
| Keratoconjunctivitis | 1 | 1/1 (100) | — | — | — |
| Organ Involvement . | No. . | NR (%) . | Stable (%) . | PR (%) . | CR (%) . |
|---|---|---|---|---|---|
| Skin3-150 | 16 | 4/16 (25) | 3/16 (19) | 9/16 (56) | — |
| Joints (flexion contractures) | 11 | 3/11 (27) | 1/11 (9) | 3/11 (27) | 4/11 (36) |
| Mouth (sores, pain) | 6 | 2/6 (33) | 1/6 (17) | 3/6 (50) | — |
| Lungs (bronchiolitis obliterans) | 4 | 2/4 (50) | 1/4 (25) | 1/4 (25) | — |
| Keratoconjunctivitis | 1 | 1/1 (100) | — | — | — |
Abbreviations: NR, no response; PR, partial response; CR, complete response.
Six sclerodermatous (3 PR, 2 stable, 1 NR), 6 lichenoid (3 PR, 1 stable, 2 NR), 4 mixed features (3 PR, 1 NR).